SCHEMBL4890241

SCHEMBL4890241

COCCCNC(=O)c1ccccc1C1CCN(CCN2C=COC(C3=CC=CC(=O)C3)=C2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
UTS2R Q9UKP6 3/20 0.36
DRD3 P35462 3/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
DRD2 P14416 2/20 0.33
TP53 P04637 1/20 0.33
HTR2A P28223 1/20 0.33
CCR3 P51677 1/20 0.33
HTR4 Q13639 1/20 0.33
ADRA1D P25100 2/20 0.33
ADRA1A P35348 2/20 0.33
ADRA1B P35368 2/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430408 0.95 UTS2R (0.37) HPGDHSD17B10ALDH1A1KDM4EUTS2R
SCHEMBL4430165 0.94 HPGD (0.39) HPGDHSD17B10ALDH1A1KDM4EUTS2R
SCHEMBL4433580 0.92 HDAC3 (0.36) HPGDHSD17B10ALDH1A1KDM4EUTS2R
SCHEMBL4440078 0.91 UTS2R (0.36) UTS2RDRD3HDAC3HDAC1DRD2
SCHEMBL4891155 0.90 UTS2R (0.36) UTS2RDRD3HDAC3HDAC1KMT2A
SCHEMBL15808512 0.90 EPHX2 (0.37) HPGDHSD17B10ALDH1A1SMN1; SMN2CCR3
SCHEMBL4890309 0.89 BCL3 (0.35) UTS2RDRD3HDAC3HDAC1KMT2A
SCHEMBL4437169 0.89 UTS2R (0.41) UTS2RHDAC3HDAC1DRD2
SCHEMBL4432414 0.89 ASAH1 (0.39) HPGDHDAC3HDAC1KMT2ASMN1; SMN2
SCHEMBL4885280 0.89 STAT3 (0.37) HPGDALDH1A1KDM4EUTS2RDRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US claimed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 HPGD 1252/4885HSD17B10 3597/4885ALDH1A1 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.